Committee for Medicinal Products for Human Use (chmp) Draft Guideline on the Evaluation of Anticancer Medicinal Products in Man

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON MEDICINAL PRODUCTS FOR THE TREATMENT OF ALZHEIMER’S DISEASE AND OTHER DEMENTIAS DRAFT AGREED BY THE EFFICACY WORKING PARTY April – June 2007 ADOPTION BY CHMP FOR RELEASE FOR CONSULTATION

Committee for Medicinal Products for Human Use (chmp) Draft Guideline on Clinical Investigation of Medicinal Products for the Treatment of Juvenile Idiopathic Arthritis

Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man

Revision 1 of this appendix refers to the addition of point 6 – ‘The role of the pathological Complete Response as an endpoint in neoadjuvant breast cancer studies’ (EMA/CHMP/151853/2014). All other content remains unchanged. For background information please see ‘Concept paper on the need to revise Condition – Specific guidance, Appendix 4 to the guideline on the evaluation of anticancer medic...

Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. 20 November 2014 EMA/CHMP/ CVMP/ SWP/169430/2012 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterina...

Committee for Medicinal Products for Human Use (chmp) Guideline on the Investigation of Manufacturing Processes for Plasma-derived Medicinal Products with Regard to Vcjd Risk